ALNY AI Stock Analysis – Buy, Hold, or Avoid?
Alnylam Pharmaceuticals, Inc. (ALNY)
Fundamentals
Alnylam Pharmaceuticals operates in the cutting-edge RNAi therapeutics segment, reflecting strong innovation but faces classic biotech volatility. While the company demonstrates meaningful revenue growth and expanding commercial efforts, profitability remains subdued owing to high R&D spending and a rich valuation. Investors should balance compelling pipeline progress against ongoing operating losses and execution risks typical of late-stage biotech firms.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
84.95% YoY
Q4 2025
Net Income
322.56% YoY
Q4 2025
Net Margin
Q4 2025
Growth Metrics
Profitability Metrics
Technical Analysis
ALNY is currently in a consolidation phase with price below key moving averages and no clear momentum direction. The presence of a death cross combined with weak trend strength suggests caution as the stock has not yet established a sustainable uptrend. Traders should monitor for a break above the 50-day SMA at $325.21 for potential bullish confirmation.
No extreme reading
Price in downtrend
Range-bound market
50 below 200 - bearish
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Alnylam Pharmaceuticals operates in the cutting-edge RNAi therapeutics segment, reflecting strong innovation but faces classic biotech volatility. While the company demonstrates meaningful revenue growth and expanding commercial efforts, profitability remains subdued owing to high R&D spending and a rich valuation. Investors should balance compelling pipeline progress against ongoing operating losses and execution risks typical of late-stage biotech firms.
Latest Earnings
Q4 2025 Earnings (Dec 31, 2025)
Earnings Per Share (EPS)
Actual
$0.82
Estimated
$1.16
Surprise
$-0.34
Surprise %
-29.31%
Revenue
Actual
$1.1B
Estimated
$1.15B
Surprise
-$52.08M
Surprise %
-4.53%
Historical Earnings
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $0.82 | $2.90 | $0.32 | $-0.01 | $0.06 | $-0.50 | $0.56 | $-0.16 |
| EPS (Estimated) | $1.16 | $0.56 | $-0.54 | $-0.89 | $-0.62 | $-0.92 | $-1.07 | $-1.12 |
| EPS Surprise | -$0.34 | +$2.34 | +$0.86 | +$0.88 | +$0.68 | +$0.42 | +$1.63 | +$0.96 |
| % Diff | -29.3% | +416.9% | +158.9% | +98.9% | +109.7% | +45.5% | +152.3% | +85.7% |
| Revenue | ||||||||
| Revenue (Actual) | $1.1B | $1.25B | $773.69M | $594.19M | $593.17M | $500.92M | $659.83M | $494.33M |
| Revenue (Estimated) | $1.15B | $959.4M | $662.87M | $585.14M | $582.61M | $532.91M | $447.22M | $428.01M |
| Revenue Surprise | -$52.08M | +$289.63M | +$110.82M | +$9.05M | +$10.56M | -$31.99M | +$212.6M | +$66.33M |
| % Diff | -4.5% | +30.2% | +16.7% | +1.5% | +1.8% | -6.0% | +47.5% | +15.5% |
Valuation
Alnylam Pharmaceuticals currently trades at a premium valuation relative to its biotech peers, reflecting strong growth and robust financial performance, particularly in 2025. Despite elevated valuation multiples, the company shows improving profitability metrics and promising pipeline developments, supported by optimistic analyst price targets with notable upside potential.
Valuation Metrics
Sentiment & Analyst Ratings
The market sentiment around ALNY is cautiously optimistic, supported by strong institutional ownership and favorable analyst price targets anticipating nearly 50% upside by the end of 2026. While technical indicators reveal some recent bearish signals and consolidation, the broader pipeline progress, profitability milestones, and strategic collaborations bolster confidence. Social media sentiment remains mixed, reflecting divided retail views amid varying growth expectations and some technical concerns.
Analyst Recommendations
Risk Assessment
Alnylam Pharmaceuticals demonstrates a strong liquidity profile and has recently achieved GAAP profitability, driving solid revenue growth primarily from its transthyretin (TTR) franchise. However, the company faces moderate to high financial risk due to a levered capital structure and competitive pressures in the ATTR space. The firm's success in executing its long-term strategy and navigating sector risks will be critical for sustaining growth and investor confidence.
Liquidity & Solvency
Frequently Asked Questions about ALNY
AI Answers: Common Questions About ALNY
Get AI-powered answers to the questions investors ask most about Alnylam Pharmaceuticals, Inc.
ALNY is a good buy for long-term investors seeking exposure to RNAi innovation, with strong revenue growth (+65% YoY), recent profitability, and a robust pipeline justifying its high P/E (138.24) and premium valuation. However, the current technical setup is weak, so short-term traders should wait for a breakout above $325.21 before entering. For long-term portfolios, current levels offer a reasonable entry given the growth outlook.
Unless your thesis has changed or you are a short-term trader reacting to technical weakness, there is no strong reason to sell; fundamentals remain strong and analyst targets imply significant upside. However, if you are risk-averse or concerned about near-term volatility, trimming exposure or waiting for a technical breakout may be prudent.
The biggest risks are execution on the pipeline (with limited late-stage catalysts in 2026), competition in the TTR space, and elevated leverage (debt-to-equity ~1.6, interest coverage near 1.0). Regulatory and pricing pressures, as well as sector volatility, also pose ongoing threats.
Analyst consensus targets $473.87 (~47% upside from current $322.11), with technical resistance at $325.21 (50-day SMA) and $393.50 (200-day SMA); support is at $317.50 and $205.87 (52-week low). A confirmed breakout above $325.21 could open the path toward higher resistance levels.
ALNY is fairly valued relative to its growth and profitability trajectory, with a high P/E (138.24) and elevated EV/EBITDA reflecting market expectations for continued expansion. Valuation is above sector averages but justified by leadership in RNAi, recent profitability, and robust revenue growth.
Fundamentally, ALNY is strong with high revenue growth, robust gross margins, and a leading innovation platform, but operating margins remain negative due to high R&D and SG&A. Liquidity is excellent (current ratio >2.7), though leverage is elevated and profitability is newly achieved.
Technically, ALNY is in a consolidation phase with price below both 50- and 200-day SMAs, a death cross active, and RSI at 49 indicating neutral momentum. No clear trend is established; traders should wait for a breakout above $325.21 with volume for bullish confirmation.
Key catalysts include upcoming clinical trial data, regulatory decisions, further commercial expansion, and earnings releases. The annual meeting and 2026 revenue guidance ($4.9B-$5.3B) are also important for sentiment and price action.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.